<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01116219</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 19/09</org_study_id>
    <secondary_id>SWS-SAKK-19-09</secondary_id>
    <secondary_id>EU-21026</secondary_id>
    <nct_id>NCT01116219</nct_id>
  </id_info>
  <brief_title>Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).</brief_title>
  <official_title>Bevacizumab, Pemetrexed and Cisplatin, or Erlotinib and Bevacizumab for Advanced Non-Squamous NSCLC Stratified by EGFR Mutation Status. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as&#xD;
      pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells,&#xD;
      either by killing the cells or by stopping them from dividing. Erlotinib hydrochloride may&#xD;
      stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is&#xD;
      not yet known whether bevacizumab given together with pemetrexed disodium and cisplatin is&#xD;
      more effective than erlotinib hydrochloride given together with bevacizumab in treating&#xD;
      patients with non-small cell lung cancer.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying giving bevacizumab together with pemetrexed disodium&#xD;
      and cisplatin to see how well it works compared with giving erlotinib hydrochloride together&#xD;
      with bevacizumab in treating patients with stage IV non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To demonstrate that tailored therapy, according to tumor histology and EGFR-mutation&#xD;
           status, and the introduction of novel drug combinations in the frontline treatment of&#xD;
           patients with stage IV non-squamous non-small cell lung cancer, is promising for further&#xD;
           investigation.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To prospectively explore molecular markers of clinical outcomes.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to EGFR(epidermal&#xD;
      growth factor receptor)-mutation status (mutated vs wildtype). Patients are assigned to 1 of&#xD;
      2 groups.&#xD;
&#xD;
        -  mutEGFR (mutated epidermal growth factor receptor) group: Patients receive bevacizumab&#xD;
           IV over 30-90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21.&#xD;
           Courses repeat every 21 days in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
        -  wtEGFR (wildtype epidermal growth factor receptor) group cohort 1:&#xD;
&#xD;
             -  Induction chemotherapy: Patients receive bevacizumab IV over 30-90 minutes,&#xD;
                pemetrexed disodium IV over 10 minutes, and cisplatin IV over 60 minutes on day 1.&#xD;
                Treatment repeats every 21 days for up to 4 courses in the absence of disease&#xD;
                progression or unacceptable toxicity.&#xD;
&#xD;
             -  Maintenance therapy: Patients without progressive disease receive bevacizumab IV&#xD;
                over 30-90 minutes and pemetrexed disodium IV over 10 minutes on day 1. Treatment&#xD;
                repeats every 21 days in the absence of disease progression.&#xD;
&#xD;
      Blood and tissue specimens are collected for EGFR and molecular markers analysis, including&#xD;
      gene expression, mutation, and pharmacogenomic analyses.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months.&#xD;
&#xD;
        -  wtEGFR (wildtype epidermal growth factor receptor) group cohort 2:&#xD;
&#xD;
             -  Induction chemotherapy: Patients receive pemetrexed disodium IV over 10 minutes,&#xD;
                and cisplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for up&#xD;
                to 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
             -  Maintenance therapy: Patients without progressive disease receive pemetrexed&#xD;
                disodium IV over 10 minutes on day 1. Treatment repeats every 21 days in the&#xD;
                absence of disease progression.&#xD;
&#xD;
      Blood and tissue specimens are collected for EGFR and molecular markers analysis, including&#xD;
      gene expression, mutation, and pharmacogenomic analyses.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 129 evaluable patients (77 in cohort 1 and 52 in cohort 2) with&#xD;
      wtEGFR status and 20 patients with mutEGFR status will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival at 6 months in stratum wtEGFR cohort 1</measure>
    <time_frame>at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from registration until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response (RECIST 1.1)</measure>
    <time_frame>up to disease progression or start of new treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (CTCAE v4.0)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular markers in tumor tissue and blood</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">149</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Stratum mut EGFR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bevacizumab 7.5 mg/kg i.v. every 3 weeks and&#xD;
Erlotinib 150 mg p.o. daily until progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum wtEGFR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort 1:&#xD;
Induction chemotherapy with&#xD;
Bevacizumab 7.5 mg/kg i.v. and&#xD;
Pemetrexed 500 mg/m2 i.v. and&#xD;
Cisplatin* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression.&#xD;
Followed by maintenance therapy in patients without disease progression with&#xD;
Bevacizumab 7.5 mg/kg i.v. and&#xD;
Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression.&#xD;
Cohort 2:&#xD;
Induction chemotherapy with&#xD;
Pemetrexed 500 mg/m2 i.v. and&#xD;
Cisplatin* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression.&#xD;
Followed by maintenance therapy in patients without disease progression with&#xD;
o Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab, erlotinib</intervention_name>
    <description>Bevacizumab 7.5 mg/kg i.v. every 3 weeks and&#xD;
Erlotinib 150 mg p.o. daily until progression.</description>
    <arm_group_label>Stratum mut EGFR</arm_group_label>
    <other_name>bevacizumab (Avastin)</other_name>
    <other_name>erlotinib (Tarceva)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab, pemetrexed, cisplatin</intervention_name>
    <description>Induction chemotherapy with&#xD;
Bevacizumab 7.5 mg/kg i.v. and&#xD;
Pemetrexed 500 mg/m2 i.v. and&#xD;
Cisplatin* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression. Followed by maintenance therapy in patients without disease progression with&#xD;
Bevacizumab 7.5 mg/kg i.v. and&#xD;
Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression.</description>
    <arm_group_label>Stratum wtEGFR</arm_group_label>
    <other_name>Bevacizumab (Avastin)</other_name>
    <other_name>pemetrexed (Alimta)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-small cell lung cancer of the following non-squamous&#xD;
             subtypes:&#xD;
&#xD;
               -  Adenocarcinoma&#xD;
&#xD;
               -  Bronchioloalveolar carcinoma&#xD;
&#xD;
               -  Large cell carcinoma&#xD;
&#xD;
          -  Stage IV disease including any of the following:&#xD;
&#xD;
               -  M1a (separate tumor nodule in a contralateral lobe, tumor with pleural nodules,&#xD;
                  or malignant pleural or pericardial effusion)&#xD;
&#xD;
               -  M1b (distant metastasis)&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 lesion (outside of irradiated areas) that can be&#xD;
             measured in ≥ 1 dimension as ≥ 10 mm (≥ 15 mm in case of lymph nodes) according to&#xD;
             RECIST 1.1&#xD;
&#xD;
          -  Paraffin-embedded or formalin-fixed diagnostic biopsy collected in the past 2 months&#xD;
             must be available&#xD;
&#xD;
          -  Must have EGFR-mutation status (mutated or wild type) confirmed by the central&#xD;
             pathologist in Basel&#xD;
&#xD;
          -  Must consent to tumor biopsy at progression&#xD;
&#xD;
          -  No intrathoracic tumors invading or abutting major blood vessels&#xD;
&#xD;
          -  No CNS metastases by mandatory CT scan (MRI within the past 3 weeks is acceptable)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  Hemoglobin ≥ 100 g/L&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT ≤ 3 times ULN (≤ 5 times ULN if liver metastases are present)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3 times ULN (≤ 5 times ULN if liver metastases are present)&#xD;
&#xD;
          -  Calculated creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Urine dipstick for proteinuria &lt; 2+&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 12 months after&#xD;
             completion of study therapy&#xD;
&#xD;
          -  Must be compliant and have geographic proximity to allow proper staging and follow-up&#xD;
&#xD;
          -  No active bleeding, including hemoptysis ≥ grade 2 (defined as bright red blood of ≥ 5&#xD;
             mL per episode within the past 4 weeks)&#xD;
&#xD;
               -  Minor hemoptysis is allowed&#xD;
&#xD;
          -  No prior malignancy within the past 5 years, except adequately treated cervical&#xD;
             carcinoma in situ or localized non-melanoma skin cancer&#xD;
&#xD;
          -  No psychiatric disorder precluding understanding of information on trial-related&#xD;
             topics, giving informed consent, or interfering with compliance for oral drug intake&#xD;
&#xD;
          -  No other medical condition that would impair the ability of the patient to participate&#xD;
             in the trial or might preclude therapy with trial drugs, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Unstable or uncompensated respiratory, cardiac, hepatic, or renal disease&#xD;
&#xD;
               -  Active infection&#xD;
&#xD;
               -  Uncontrolled diabetes mellitus&#xD;
&#xD;
               -  Uncontrolled arterial hypertension (i.e., BP ≥ 150/100 mm Hg despite optimal&#xD;
                  medical therapy)&#xD;
&#xD;
               -  History of myocardial infarction in the last 3 months&#xD;
&#xD;
               -  History of hemorrhagic disorders&#xD;
&#xD;
               -  Non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
               -  Significant traumatic injury within the past 28 days&#xD;
&#xD;
          -  No known hypersensitivity to trial drugs or to any other component of the trial drugs&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior chemotherapy or molecular-targeted therapy for metastatic disease&#xD;
             (neoadjuvant or adjuvant chemotherapy allowed if terminated &gt; 6 months ago)&#xD;
&#xD;
          -  No prior radiotherapy to lesion(s) selected for measurement&#xD;
&#xD;
          -  At least 30 days since prior yellow fever vaccination&#xD;
&#xD;
          -  At least 30 days since prior experimental drugs, anticancer therapy, or treatment in a&#xD;
             clinical trial&#xD;
&#xD;
          -  More than 28 days since major surgical procedure or open biopsy&#xD;
&#xD;
          -  No concurrent full-dose oral, intravenous, or subcutaneous anticoagulants (low-dose&#xD;
             heparin or aspirin [≤ 325 mg p.o. daily] allowed)&#xD;
&#xD;
          -  No concurrent herbal extracts or drugs contraindicated for use with trial drugs&#xD;
&#xD;
          -  No concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anti-neoplastic or anti-tumor agents, including chemotherapy,&#xD;
             immunotherapy, or hormonal anticancer therapy&#xD;
&#xD;
          -  No concurrent Asasantin® (acetylsalicylic acid and dipyridamole) or Plavix®&#xD;
             (clopidogrel bisulfate)&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          -  Before registration, patient must give written informed consent for participation in&#xD;
             the trial including tumor biopsy at progression.&#xD;
&#xD;
          -  Patient must have the capability to understand informed consent and information given&#xD;
             by the investigator on the trial.&#xD;
&#xD;
          -  Non-small cell lung cancer (NSCLC), predominant non-squamous subtype (adenocarcinoma,&#xD;
             bronchioloalveolar carcinoma, and large cell carcinoma) confirmed by the central&#xD;
             pathologist in Basel.&#xD;
&#xD;
          -  NSCLC stage IV according to the 7th edition of the TNM classification, including M1a&#xD;
             (separate tumor nodule in a contralateral lobe, tumor with pleural nodules or&#xD;
             malignant pleural or pericardial effusion) and/or M1b (distant metastasis).&#xD;
&#xD;
          -  Most recent diagnostic biopsy paraffin-embedded or only formalin-fixed and sufficient&#xD;
             for further molecular analysis as determined by central pathologist in Basel.&#xD;
&#xD;
          -  EGFR mutation status determined by local or central pathologist in Basel.&#xD;
&#xD;
          -  EDTA blood samples (2 x 5 mL) for translational research projects will be taken before&#xD;
             treatment start.&#xD;
&#xD;
          -  WHO performance status 0-1 (see Appendix 4).&#xD;
&#xD;
          -  Age ≥ 18 years and legally competent person.&#xD;
&#xD;
          -  Measurable disease, defined as at least one lesion (outside of irradiated areas) that&#xD;
             can be measured in at least one dimension as ≥ 10 mm (≥ 15 mm in case of lymph&#xD;
             nodes)according to RECIST v1.1&#xD;
&#xD;
          -  Adequate hematological values: Hemoglobin ≥ 100 g/L, neutrophils ≥ 1.5 x 109/L,&#xD;
             platelets ≥ 100 x 109/L&#xD;
&#xD;
          -  Adequate hepatic function: Bilirubin ≤ 1.5 x ULN, ALT and AP ≤ 3 x ULN (≤ 5 x ULN in&#xD;
             case of liver metastases)&#xD;
&#xD;
          -  Adequate renal function: Calculated creatinine clearance ≥ 60 mL/min (according to the&#xD;
             formula of Cockroft-Gault)&#xD;
&#xD;
          -  Urine dipstick for proteinuria &lt; 2+&#xD;
&#xD;
          -  Women are not breastfeeding. Women with child-bearing potential are using effective&#xD;
             contraception (see 9.2.4 and 9.3.5), are not pregnant and agree not to become pregnant&#xD;
             during participation in the trial and during the 12 months thereafter. A negative&#xD;
             pregnancy test before inclusion into the trial is required for all women with&#xD;
             childbearing potential. Men agree not to father a child during participation in the&#xD;
             trial or during the 12 months thereafter.&#xD;
&#xD;
          -  Patient compliance and geographic proximity allow proper staging and follow-up.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Diagnosis of SCLC, predominantly squamous NSCLC (&gt;50% by central pathology review) or&#xD;
             combined SCLC-NSCLC.&#xD;
&#xD;
          -  Patients with intrathoracic tumors invading or abutting major blood vessels.&#xD;
&#xD;
          -  Prior chemotherapy or molecular targeted therapy for metastatic disease, with the&#xD;
             exception of neoadjuvant or adjuvant chemotherapy if terminated 6 months before&#xD;
             registration. Prior radiotherapy to lesion(s) selected for measurement.&#xD;
&#xD;
          -  CNS metastases by mandatory CT-scan (MRI is acceptable).&#xD;
&#xD;
          -  Anticoagulation, with the exception of low dose heparin or aspirin (≤ 325 mg p.o.&#xD;
             daily).&#xD;
&#xD;
          -  Active bleeding, including hemoptysis ≥ grade 2 (defined as bright red blood of at&#xD;
             least 5 mL per episode within the last 4 weeks of registration). Minor hemoptysis is&#xD;
             allowed.&#xD;
&#xD;
          -  Yellow fever vaccination within the 30 days prior to registration.&#xD;
&#xD;
          -  Previous malignancy within 5 years with the exception of adequately treated cervical&#xD;
             carcinoma in situ or localized non-melanoma skin cancer.&#xD;
&#xD;
          -  Psychiatric disorder precluding understanding of information on trial related topics,&#xD;
             giving informed consent, or interfering with compliance for oral drug intake.&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs or other anti-cancer therapy,&#xD;
             treatment in a clinical trial within 30 days prior to trial entry.&#xD;
&#xD;
          -  Evidence of other medical condition which would impair the ability of the patient to&#xD;
             participate in the trial or might preclude therapy with trial drugs (e.g. unstable or&#xD;
             uncompensated respiratory, cardiac, hepatic or renal disease, active infection,&#xD;
             uncontrolled diabetes mellitus; uncontrolled arterial hypertension ≥ 150/100 mmHg,&#xD;
             history of myocardial infarction in the last 3 months, history of hemorrhagic&#xD;
             disorders, non healing wound, ulcer or bone fracture)&#xD;
&#xD;
          -  Major surgical procedure, open biopsy or significant traumatic injury within 28 days&#xD;
             prior to registration&#xD;
&#xD;
          -  Known hypersensitivity to trial drugs or hypersensitivity to any other component of&#xD;
             the trial drugs.&#xD;
&#xD;
          -  Any concomitant drugs contraindicated for use with the trial drugs according to the&#xD;
             Swissmedic-approved product information.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Gautschi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Luzerner Kantonsspital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adrian Ochsenbein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas Mach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Cantonal Universitaire de Geneve HUG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sacha Rothschild, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Claraspital AG</name>
      <address>
        <city>Basel</city>
        <zip>CH-4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Cancer Research Center at University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni</name>
      <address>
        <city>Bellinzona</city>
        <zip>CH-6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Biel</name>
      <address>
        <city>Biel</city>
        <zip>CH-2501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <zip>CH-4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>1700</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Pluridisciplinaire d' Oncologie</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Liestal</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzerne</city>
        <zip>CH-6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalspital</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spital Uster</name>
      <address>
        <city>Uster</city>
        <zip>8610</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>CH-8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8044</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkozentrum Hirslanden</name>
      <address>
        <city>Zürich</city>
        <zip>8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Gautschi O, Rothschild SI, Li Q, Matter-Walstra K, Zippelius A, Betticher DC, Früh M, Stahel RA, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein AF; Swiss Group for Clinical Cancer Research. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clin Lung Cancer. 2017 May;18(3):303-309. doi: 10.1016/j.cllc.2016.11.007. Epub 2016 Nov 23.</citation>
    <PMID>27993482</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 27, 2010</study_first_submitted>
  <study_first_submitted_qc>May 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2010</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

